We identify a novel vulnerability in ATL resulting from the relationship of the synthetic lethality between the loss of NDRG2 expression and cytoplasmic PRMT5/MEP50 activity and reveal a functional and promising therapeutic target for the treatment of NDRG2low tumours. The gene discussed is PRMT5; the disease is neoplasm.